Proteonomix commences UMK-121 study with patient screening
The University of Medicine & Dentistry of New Jersey together with the company screened the around 30 patients for the inclusion or exclusion in the study. Proteonomix chief
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.
The primary endpoint of the placebo-controlled, multi-center study was achieved in 54% patients administered with pregabalin, compared to 70.7% patients in the placebo group. A statistically significant difference